- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01319864
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 500 children are diagnosed with AML every year, of whom around 60% are cured with current regimens based on anthracyclines and high dose cytarabine with or without stem cell transplant (SCT). Among the remaining 40% who are refractory or who relapse, outcome is dismal. Additionally, 20-30% of patients with childhood ALL relapse or become refractory to frontline therapies. The prognosis is poor in this patient population, particularly in patients with second or subsequent relapse and those who relapse following SCT. These patients present myriad challenges, as they usually have received a high cumulative anthracycline dose, and in the case of SCT, may have had significant organ toxicities and/or total body irradiation (TBI). Therefore, new therapeutic strategies need to be identified to enhance possible improved outcomes.
Recently, scientists have described a resistant, quiescent population of leukemia cells that have limitless self-renewal potential. The identification of these "leukemia stem cells" (LSCs) provides an additional strategy in treating and preventing relapsed/refractory acute leukemia. One mechanism for resistance to treatment is the protection afforded LSCs via the interaction between stem cell derived growth factor (CXCL-12/SDF-1α) and its receptor, CXCR4. These interactions are implicated in chemotaxis, homing, and survival/apoptosis of hematopoietic stem cells and progenitor cells. All AML and ALL cells express CXCR4 and SDF-1α. AMD3100 (plerixafor, MOBOZIL®) is a bicyclam that blocks CXCL-12 binding to and signaling through CXCR4, thus disrupting tumor-stroma interactions and mobilizing leukemia cells from their protective stromal environment. Plerixafor is currently FDA approved for use in stem cell mobilization for autologous transplantation in hematologic malignancies. Clinical trials in adult patients with relapsed AML have demonstrated promising results when combining plerixafor with cytotoxic chemotherapy.
This Phase I clinical trial will be the first to test the concept of a "chemosensitization" approach in children using Plerixafor. Patients aged 3 to 30 with relapsed/refractory AML, ALL or MDS will receive Plerixafor followed 4 hours later with combination chemotherapy consisting of etoposide and cytarabine daily for five days. We will determine the safety and tolerability of Plerixafor in combination with cytarabine and etoposide in pediatric and young adults with relapsed/refractory acute leukemias. The secondary objectives of this study will quantify the peripheral blood mobilization of blasts in response to Plerixafor using flow cytometry, measure initial CXCR4 expression on leukemic blasts and correlate with response, and determine the change in CXCR4 expression after protocol therapy. Finally, we will determine the pharmacokinetics of Plerixafor when administered with cytotoxic chemotherapy in this patient population.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80045
- The Children's Hospital of Denver
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta/Emory University
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Johns Hopkins Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- The Children's Mercy Hospital and Clinics
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Hershey Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- >= 3 years of age and <30 years old at study entry
- diagnosis of relapsed/refractory AML, ALL, secondary AML/MDS, or acute leukemia of ambiguous lineage and meet the following criteria:
- AML/MDS or leukemia with ambiguous lineage must have >5% blast in bone marrow
- ALL must have an M3 marrow
- ALL and AML must not have CNS disease
- patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy prior to entering study
- Karnofsky score >50% for patients >16 years of age and Lansky >50% for patients <= 16 years of age
- adequate renal and hepatic function as defined in protocol
- adequate cardiac function as defined in protocol
Exclusion Criteria:
- ALL and AML patients with CNS disease
- Absolute blast count greater than 50,000/mcl
- Systemic fungal, bacterial, viral or other infection without improvement despite appropriate antibiotics or other treatment
- Significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance
- Patients who have second cancer, not including secondary AML
- Patients who are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Plerixafor, Dose Escalation
Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
|
Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Plerixafor given in combination with chemotherapy
Time Frame: 6 months post final enrollment
|
To determine the safety and tolerability of plerixafor in combination with reinduction chemotherapy in pediatric and young adult patients with relapsed/refractory acute leukemia (AML/MDS and ALL)
|
6 months post final enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: 6 months post completion of treatment for final enrollment
|
To estimate the response rate, within the context of a Phase I study, of Plerixafor given in sequential combination with cytarabine/etoposide (AE) in patients with relapsed or refractory ALL and AML/MDS.
|
6 months post completion of treatment for final enrollment
|
Measure Peak Plasma Concentration (Cmax) of Plerixafor using serial peripheral blood sampling
Time Frame: 12 months following last sample collection
|
Plasma pharmacokinetic parameters are estimated by noncompartmental analysis using PhoenixWinNonlin 7.0 (Certara) and are estimated from the observed concentration-time data.
|
12 months following last sample collection
|
Leukemic blast mobilization
Time Frame: 12 months after final sample collection
|
To measure peripheral blood mobilization of leukemic blasts by flow cytometry by comparing blood samples obtained before and after dose 1 of plerixafor, and to correlate degree of mobilization (expressed as % increase in circulating blasts) with response.
|
12 months after final sample collection
|
CXCR4 expression on leukemic blasts
Time Frame: 12 months after last patient completes therapy
|
To measure the quantitative expression of CXCR4 on leukemic blasts at baseline and end of first course of treatment using flow cytometry and qRT-PCR, and correlate expression level with response.
|
12 months after last patient completes therapy
|
Measure Area Under the Concentration-Time Curve (AUC) of Plerixafor using serial peripheral blood sampling
Time Frame: 12 months following last sample collection
|
Plasma pharmacokinetic parameters are estimated by noncompartmental analysis using PhoenixWinNonlin 7.0 (Certara) and are estimated from the observed concentration-time data.
|
12 months following last sample collection
|
Measure terminal half life (t1/2) of Plerixafor using serial peripheral blood sampling
Time Frame: 12 months following last sample collection
|
Plasma pharmacokinetic parameters are estimated by noncompartmental analysis using PhoenixWinNonlin 7.0 (Certara) and are estimated from the observed concentration-time data.
|
12 months following last sample collection
|
Measure systemic clearance of Plerixafor using serial peripheral blood sampling
Time Frame: 12 months following last sample collection
|
Plasma pharmacokinetic parameters are estimated by noncompartmental analysis using PhoenixWinNonlin 7.0 (Certara) and are estimated from the observed concentration-time data.
|
12 months following last sample collection
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Todd Cooper, DO, Emory University/Children's Healthcare of Atlanta
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00047475
- POETIC Plerixafor (Other Identifier: Other)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Hebei Senlang Biotechnology Inc., Ltd.Recruiting
-
Institute of Hematology & Blood Diseases Hospital...Recruiting
-
Beijing Immunochina Medical Science & Technology...Completed
-
Stichting Hemato-Oncologie voor Volwassenen NederlandWithdrawn
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
Clinical Trials on Plerixafor Dose Escalation
-
E. Steve WoodleSanofi-SynthelaboUnknown
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Istituto Clinico HumanitasRecruitingNon Small Cell Lung Cancer | Lung MetastasesItaly
-
Emory UniversityCompletedBrain Metastasis | NeoplasmUnited States